Navigation Links
Mylan Reports a 19% Increase in First Quarter 2013 Adjusted Diluted EPS to $0.62
Date:5/2/2013

in deferred revenue

16Income tax items

—18Adjusted cash provided by operating activities

$

90$

69 

(a)
Adjusted gross profit is calculated as total revenues less adjusted cost of sales.  Adjusted gross margin is calculated as adjusted gross profit divided by total revenue.

(b)
Adjusted earnings from operations is calculated as adjusted gross profit less adjusted total operating expenses.

(c)
Adjustment represents exclusion of activity related to Mylan's investment in a clean energy partnership, the activities of which qualify for income tax credits under section 45 of the Internal Revenue Code. Certain prior period insignificant amounts of other revenue, cost of sales, operating expenses and the related EBITDA and Adjusted EBITDA amounts have been reclassified to other income (expense), net, as losses from equity affiliates. The reclassifications had no impact on the previously reported net earnings and diluted EPS attributable to Mylan Inc. common shareholders or adjusted net earnings and adjusted diluted EPS attributable to Mylan Inc. 

 


'/>"/>
SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Mylan Launches Generic Version of Zyprexa® Tablets
2. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
3. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
4. Mylan Launches Generic Lipitor® in Five European Countries
5. Mylan Launches Generic Version of Plavix® Tablets
6. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
7. Mylan Launches Generic Version of Viramune® Tablets
8. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
9. Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovions Brovana® Product
10. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
11. Mylan Launches Generic Version of Lipitor®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015  Medical Care Alert, a leading national ... announced availability of its new HOME & AWAY ELITE ... the neck or on the hip, the small two-ounce ... USA using the AT&T Wireless ... generation in mobile and automatic fall detection medical alert ...
(Date:7/29/2015)... YORK , July 29, 2015 /PRNewswire/ ... a new research report "Global Industry Insight: ... to 2020" with market overview, trends, DRO analysis, ... analysis, recent developments, competitive scenario and top ... http://photos.prnewswire.com/prnh/20150727/756778 ) Microfluidic devices  ...
(Date:7/29/2015)... 2015 TAKE Solutions Ltd., a global business technology ... market for the Life Sciences sector, by setting up ... investment of 3 million USD . Intelent aims to ... (according to projections by McKinsey) by providing clients offerings in ... Noting the exponential ...
Breaking Medicine Technology:New Medical Care Alert Pendant Combines GPS, Cellular Voice, and Automatic Fall Detection 2New Medical Care Alert Pendant Combines GPS, Cellular Voice, and Automatic Fall Detection 3New Medical Care Alert Pendant Combines GPS, Cellular Voice, and Automatic Fall Detection 4Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 2Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 3Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 4Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 5TAKE Solutions Creates a New Subsidiary for Life Sciences Big Data in the US 2TAKE Solutions Creates a New Subsidiary for Life Sciences Big Data in the US 3
... 2011 Reportlinker.com announces that a ... in its catalogue: ... - Asia-Pacific, Especially India and China, ... and Regulatory Pressures in Western Pharmaceutical ...
... Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX ... that it has entered into agreements with Quintiles ... Inc. (ICS) to support the anticipated launch of ... be approved by the Food and Drug Administration ...
Cached Medicine Technology:Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 2Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 3Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 4Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 5Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 6Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 7Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 8Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 9Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 10Pacira Pharmaceuticals, Inc. Expands EXPAREL™ Commercial Team Infrastructure 2Pacira Pharmaceuticals, Inc. Expands EXPAREL™ Commercial Team Infrastructure 3Pacira Pharmaceuticals, Inc. Expands EXPAREL™ Commercial Team Infrastructure 4Pacira Pharmaceuticals, Inc. Expands EXPAREL™ Commercial Team Infrastructure 5
(Date:7/29/2015)... ... July 29, 2015 , ... The report “Atherosclerosis - ... Atherosclerosis is a slow, progressive disease that may start in childhood. The report ... best-in-class products. Complete report on Atherosclerosis Pipeline with 78 market data tables and ...
(Date:7/29/2015)... ... July 29, 2015 , ... Topical BioMedics, ... Topricin® Pain Relief and Healing Cream designated as the nonprofit’s natural pain reliever ... actively addressing Line of Duty Deaths (LODD) and the high rate of pain ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... anticipating testing regulations imposed by the FDA for nicotine laced liquid products. Their ... electronic cigarettes have raised considerably. E-Cigarettes are particularly troublesome to addiction professionals as ...
(Date:7/29/2015)... San Fernando Valley, CA (PRWEB) , ... July 29, 2015 , ... ... offering a special promotional price on Ultherapy. For a limited time only, patients can ... Ultherapy is an option for patients who prefer a non-invasive treatment and have ...
(Date:7/29/2015)... ... July 29, 2015 , ... Wedding season is in full swing, which means bridal beauty ... of looking good on the big day. Every bride wants to look and feel beautiful, ... , According to a recent study by the American Academy of ...
Breaking Medicine News(10 mins):Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 3Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 4Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 5Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 6Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 2Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 3Health News:San Fernando Valley Dermatology Office, Castle Dermatology Institute, is Now Offering a Promotional Price on Ultherapy 2Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 2Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 3
... ImmuKnow(R) and anti-HLA antibody assays both contribute to ... ... immunosuppression, COLUMBIA, Md., June 1 Data developed ... presented,today at the American Transplantation Congress in Toronto, Canada, suggest,that cell-mediated ...
... treatment of choice for advanced, metastatic prostate cancer has ... testosterone the hormone that fuels prostate-cancer growth ... drugs. While such therapy buys time for patients, it ... resistant to the androgen deprivation and continues to grow. ...
... everolimus almost doubled survival time with pancreatic, kidney ... News) -- Patients diagnosed with pancreatic cancer -- ... doubled their overall survival when the cancer drug ... , Unfortunately, only about 15 percent of pancreatic ...
... drug prolonged progression-free survival, study finds , , SATURDAY, ... Avastin to chemotherapy lengthened progression-free survival in women ... Previous studies have found that adding Avastin (bevacizumab) ... with advanced breast cancer actually doubled progression-free survival. ...
... likely to have diminished ovarian reserve producing viable ... News) -- Chemotherapy may reduce fertility in breast ... researchers at Boston,s Dana-Farber Cancer Institute. , They ... chemotherapy following surgery were more likely than women ...
... young children has been linked to a significant number ... to recommend against their use for children less than ... efficacy, there has been little research on patterns of ... Now, a new study from the Emergency Medicine Network ...
Cached Medicine News:Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 2Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 3Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 2Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 3Health News:New Hope for Tough-to-Treat Cancers 2Health News:New Hope for Tough-to-Treat Cancers 3Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 2Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 3Health News:Chemo May Limit Fertility in Breast Cancer Survivors 2Health News:Study examines cold medication use in young children 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: